Literature DB >> 8771061

Iron in parkinsonian and control substantia nigra--a Mössbauer spectroscopy study.

J Gałazka-Friedman1, E R Bauminger, A Friedman, M Barcikowska, D Hechel, I Nowik.   

Abstract

We used Mössbauer spectroscopy to study the iron content, the redox state, and the binding site of iron in substantia nigra (SN) from parkinsonian (PD) and control brains. Measurements performed on fresh-frozen, formalin-fixed, and lyophilized samples demonstrated the presence of ferric (Fe3+) iron only, both in PD and control SN. Ferrous iron, if present at all, may represent at most 5% of the total iron. We found no difference in the total amount of iron in SN between PD and control brains. The Mössbauer spectra observed at 4.1 K in fresh (frozen or lyophilized) samples were different from those obtained in formalin-fixed (frozen or lyophilized) samples. In the fresh samples, only ferritin-like iron was observed, whereas in the samples frozen or lyophilized from formalin, non-ferritin iron was detected.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8771061     DOI: 10.1002/mds.870110104

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  29 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies.

Authors:  M Fasano; B Bergamasco; L Lopiano
Journal:  J Neural Transm (Vienna)       Date:  2006-05-12       Impact factor: 3.575

Review 3.  Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients.

Authors:  Dominic J Hare; Manfred Gerlach; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2012-09-13       Impact factor: 3.575

4.  Changing iron content of the mouse brain during development.

Authors:  Gregory P Holmes-Hampton; Mrinmoy Chakrabarti; Allison L Cockrell; Sean P McCormick; Louise C Abbott; Lora S Lindahl; Paul A Lindahl
Journal:  Metallomics       Date:  2012-07-19       Impact factor: 4.526

Review 5.  Parkinson's disease and iron.

Authors:  Hideki Mochizuki; Chi-Jing Choong; Kousuke Baba
Journal:  J Neural Transm (Vienna)       Date:  2020-02-05       Impact factor: 3.575

Review 6.  Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.

Authors:  L Zecca; D Tampellini; M Gerlach; P Riederer; R G Fariello; D Sulzer
Journal:  Mol Pathol       Date:  2001-12

7.  Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.

Authors:  Guangwei Du; Mechelle M Lewis; Christopher Sica; Lu He; James R Connor; Lan Kong; Richard B Mailman; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

8.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

Review 9.  Iron accumulation in Parkinson's disease.

Authors:  Hideki Mochizuki; Toru Yasuda
Journal:  J Neural Transm (Vienna)       Date:  2012-10-16       Impact factor: 3.575

Review 10.  Iron in chronic brain disorders: imaging and neurotherapeutic implications.

Authors:  James Stankiewicz; S Scott Panter; Mohit Neema; Ashish Arora; Courtney E Batt; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.